Hla-a2.1 binding peptides and their uses
CA 2248667 C · Owner: Pharmexa Inc. · Inventors: Grey, Howard M.; Sidney, John; Sette, Alessandro
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA-A2.1 allele and inducing T cell activation in T cells restricted by the A2.1 allele. The peptides are useful to elicit an immune response against a desired antigen.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 21, 1997 and granted June 5, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 21, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 21, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.